154 related articles for article (PubMed ID: 32641388)
1. Metformin and 2-Deoxyglucose Collaboratively Suppress Human CD4
Tan SY; Kelkar Y; Hadjipanayis A; Shipstone A; Wynn TA; Hall JP
J Immunol; 2020 Aug; 205(4):957-967. PubMed ID: 32641388
[TBL] [Abstract][Full Text] [Related]
2. Metabolic plasticity of human T cells: Preserved cytokine production under glucose deprivation or mitochondrial restriction, but 2-deoxy-glucose affects effector functions.
Renner K; Geiselhöringer AL; Fante M; Bruss C; Färber S; Schönhammer G; Peter K; Singer K; Andreesen R; Hoffmann P; Oefner P; Herr W; Kreutz M
Eur J Immunol; 2015 Sep; 45(9):2504-16. PubMed ID: 26114249
[TBL] [Abstract][Full Text] [Related]
3. Human Plasmacytoid and Monocyte-Derived Dendritic Cells Display Distinct Metabolic Profile Upon RIG-I Activation.
Fekete T; Sütö MI; Bencze D; Mázló A; Szabo A; Biro T; Bacsi A; Pazmandi K
Front Immunol; 2018; 9():3070. PubMed ID: 30622542
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.
Kim EH; Lee JH; Oh Y; Koh I; Shim JK; Park J; Choi J; Yun M; Jeon JY; Huh YM; Chang JH; Kim SH; Kim KS; Cheong JH; Kim P; Kang SG
Neuro Oncol; 2017 Feb; 19(2):197-207. PubMed ID: 27571886
[TBL] [Abstract][Full Text] [Related]
5. Glycolytic reprogramming of macrophages activated by NOD1 and TLR4 agonists: No association with proinflammatory cytokine production in normoxia.
Murugina NE; Budikhina AS; Dagil YA; Maximchik PV; Balyasova LS; Murugin VV; Melnikov MV; Sharova VS; Nikolaeva AM; Chkadua GZ; Pinegin BV; Pashenkov MV
J Biol Chem; 2020 Mar; 295(10):3099-3114. PubMed ID: 32005665
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting Glycolysis and ATP Production Attenuates IL-33-Mediated Mast Cell Function and Peritonitis.
Caslin HL; Taruselli MT; Haque T; Pondicherry N; Baldwin EA; Barnstein BO; Ryan JJ
Front Immunol; 2018; 9():3026. PubMed ID: 30619366
[TBL] [Abstract][Full Text] [Related]
7. Low-dose 2-deoxy glucose stabilises tolerogenic dendritic cells and generates potent in vivo immunosuppressive effects.
Christofi M; Le Sommer S; Mölzer C; Klaska IP; Kuffova L; Forrester JV
Cell Mol Life Sci; 2021 Mar; 78(6):2857-2876. PubMed ID: 33074350
[TBL] [Abstract][Full Text] [Related]
8. Leukemia cells demonstrate a different metabolic perturbation provoked by 2-deoxyglucose.
Miwa H; Shikami M; Goto M; Mizuno S; Takahashi M; Tsunekawa-Imai N; Ishikawa T; Mizutani M; Horio T; Gotou M; Yamamoto H; Wakabayashi M; Watarai M; Hanamura I; Imamura A; Mihara H; Nitta M
Oncol Rep; 2013 May; 29(5):2053-7. PubMed ID: 23440281
[TBL] [Abstract][Full Text] [Related]
9. Bioenergetic properties of human sarcoma cells help define sensitivity to metabolic inhibitors.
Issaq SH; Teicher BA; Monks A
Cell Cycle; 2014; 13(7):1152-61. PubMed ID: 24553119
[TBL] [Abstract][Full Text] [Related]
10. 2-Deoxy-D-glucose impedes T cell-induced apoptosis of keratinocytes in oral lichen planus.
Wang F; Zhang J; Zhou G
J Cell Mol Med; 2021 Nov; 25(21):10257-10267. PubMed ID: 34672419
[TBL] [Abstract][Full Text] [Related]
11. PKM2-dependent metabolic reprogramming in CD4
Lü S; Deng J; Liu H; Liu B; Yang J; Miao Y; Li J; Wang N; Jiang C; Xu Q; Wang X; Feng J
J Mol Med (Berl); 2018 Jun; 96(6):585-600. PubMed ID: 29732501
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
Mert I; Chhina J; Allo G; Dai J; Seward S; Carey MS; Llaurado M; Giri S; Rattan R; Munkarah AR
Gynecol Oncol; 2017 Aug; 146(2):319-326. PubMed ID: 28545687
[TBL] [Abstract][Full Text] [Related]
13. Metabolic preconditioning in CD4+ T cells restores inducible immune tolerance in lupus-prone mice.
Wilson CS; Stocks BT; Hoopes EM; Rhoads JP; McNew KL; Major AS; Moore DJ
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34403367
[TBL] [Abstract][Full Text] [Related]
14. Metformin Inhibits the Type 1 IFN Response in Human CD4
Titov AA; Baker HV; Brusko TM; Sobel ES; Morel L
J Immunol; 2019 Jul; 203(2):338-348. PubMed ID: 31160534
[TBL] [Abstract][Full Text] [Related]
15. The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R.
Zhong D; Xiong L; Liu T; Liu X; Liu X; Chen J; Sun SY; Khuri FR; Zong Y; Zhou Q; Zhou W
J Biol Chem; 2009 Aug; 284(35):23225-33. PubMed ID: 19574224
[TBL] [Abstract][Full Text] [Related]
16. Metformin attenuates hepatoma cell proliferation by decreasing glycolytic flux through the HIF-1α/PFKFB3/PFK1 pathway.
Hu L; Zeng Z; Xia Q; Liu Z; Feng X; Chen J; Huang M; Chen L; Fang Z; Liu Q; Zeng H; Zhou X; Liu J
Life Sci; 2019 Dec; 239():116966. PubMed ID: 31626790
[TBL] [Abstract][Full Text] [Related]
17. Chronic Dietary Administration of the Glycolytic Inhibitor 2-Deoxy-D-Glucose (2-DG) Inhibits the Growth of Implanted Ehrlich's Ascites Tumor in Mice.
Singh S; Pandey S; Bhatt AN; Chaudhary R; Bhuria V; Kalra N; Soni R; Roy BG; Saluja D; Dwarakanath BS
PLoS One; 2015; 10(7):e0132089. PubMed ID: 26135741
[TBL] [Abstract][Full Text] [Related]
18. Energy metabolism of leukemia cells: glycolysis versus oxidative phosphorylation.
Suganuma K; Miwa H; Imai N; Shikami M; Gotou M; Goto M; Mizuno S; Takahashi M; Yamamoto H; Hiramatsu A; Wakabayashi M; Watarai M; Hanamura I; Imamura A; Mihara H; Nitta M
Leuk Lymphoma; 2010 Nov; 51(11):2112-9. PubMed ID: 20860495
[TBL] [Abstract][Full Text] [Related]
19. Glycolytic Stimulation Is Not a Requirement for M2 Macrophage Differentiation.
Wang F; Zhang S; Vuckovic I; Jeon R; Lerman A; Folmes CD; Dzeja PP; Herrmann J
Cell Metab; 2018 Sep; 28(3):463-475.e4. PubMed ID: 30184486
[TBL] [Abstract][Full Text] [Related]
20. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways.
Wang Y; Xu W; Yan Z; Zhao W; Mi J; Li J; Yan H
J Exp Clin Cancer Res; 2018 Mar; 37(1):63. PubMed ID: 29554968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
